Schulze H, Kaldenhoff H, Senge T
Department of Urology, Ruhr University, Herne, FRG.
Urol Int. 1988;43(4):193-7. doi: 10.1159/000281336.
In order to evaluate the proposed benefit of complete androgen blockade in the treatment of patients with advanced prostatic cancer, we initiated a multicenter prospective and randomized study. At the time of this report 99 patients with newly diagnosed, previously untreated prostatic cancer were randomly distributed to one of the following treatments: group I, orchiectomy plus antiandrogen Flutamide; group II, depot LH-RH analog Zoladex plus Flutamide; group III, orchiectomy alone, and group IV, Zoladex alone. Our preliminary data fail to demonstrate a superiority of total androgen blockade over partial androgen blockade in the treatment of patients with advanced cancer of the prostate.
为了评估在晚期前列腺癌患者治疗中采用完全雄激素阻断疗法的预期益处，我们开展了一项多中心前瞻性随机研究。在撰写本报告时，99例新诊断的、此前未接受过治疗的前列腺癌患者被随机分配至以下治疗组之一：第一组，睾丸切除术加抗雄激素药物氟他胺；第二组，长效促性腺激素释放激素类似物（LHRH）戈舍瑞林加氟他胺；第三组，单纯睾丸切除术；第四组，单纯戈舍瑞林。我们的初步数据未能证明在晚期前列腺癌患者治疗中，完全雄激素阻断疗法优于部分雄激素阻断疗法。
